Patients detected with increased circulating ESR1 mutation without tumor progression were randomized to remain on current therapy or to switch to fulvestrant (known to be more effective in the presence of ESR1 mutation) in combination with palbociclib. This evidence concerns the gene ESR1 and neoplasm.